Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same

Patent metadata

Field	Value
Publication number	US-9895378-B2
Application number	US-201514656899-A
Country	US
Kind code	B2
Filing date	Mar 13, 2015
Priority date	Mar 14, 2014
Publication date	Feb 20, 2018
Grant date	Feb 20, 2018

Abstract

The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles.

First claim

What is claimed is:

1. A therapeutic nanoparticle comprising:
a therapeutic agent selected from the group consisting of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea and pharmaceutically acceptable salt thereof;
a polymer selected from the group consisting of diblock poly(lactic) acid-poly(ethylene)glycol (PLA-PEG) copolymer, diblock poly(lactic acid-co-glycolic acid)-poly(ethylene)glycol (PLGA-PEG) copolymer, and combinations thereof; and
a substantially hydrophobic acid selected from the group consisting of dioctyl sulfosuccinic acid, 1-hydroxy-2-naphthoic acid, dodecyl sulfuric acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, pamoic acid, undecanoic acid, and combinations thereof;
wherein the substantially hydrophobic acid and the therapeutic agent form a hydrophobic ion pair that is encapsulated in the therapeutic nanoparticle; and
wherein the hydrophobic ion pair is dispersed throughout a polymeric matrix comprising the polymer,
wherein PLA-PEG-GL is additionally present, wherein targeting ligand GL has the following structure:

2. The therapeutic nanoparticle according to claim 1 , wherein the pK a of the protonated therapeutic agent is at least about 1.0 pK a units greater than the pK a of the substantially hydrophobic acid.

3. The therapeutic nanoparticle according to claim 1 comprising about 0.2 to about 20 weight percent of the therapeutic agent.

4. The therapeutic nanoparticle according to claim 1 comprising about 50 to about 99.75 weight percent of the polymer, and wherein the therapeutic nanoparticle comprises about 10 to about 30 weight percent poly(ethylene)glycol.

5. The therapeutic nanoparticle according to claim 1 comprising about 0.05 to about 30 weight percent of the substantially hydrophobic acid.

6. The therapeutic nanoparticle according to claim 1 comprising:
1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea;
and PLA-PEG (in a 16:5 molar ratio) in a weight ratio of about 1:7 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea:PLA-PEG.

7. The therapeutic nanoparticle according to claim 1 comprising:
1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea;
and PLA-PEG (in a 16:5 molar ratio) in a weight ratio of about 1:5 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea:PLA-PEG.

8. The therapeutic nanoparticle according to claim 1 comprising:
1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea;
and PLA-PEG (in a 16:5 molar ratio) in a weight ratio of about 1:14 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea:PLA-PEG.

9. The therapeutic nanoparticle according to claim 1 , wherein the molar ratio of the substantially hydrophobic acid to the therapeutic agent ranges from about 0.25:1 to about 2:1.

10. The therapeutic nanoparticle according to claim 1 , wherein the molar ratio of the substantially hydrophobic acid to the therapeutic agent is about 0.25:1 to about 1:1.

11. The therapeutic nanoparticle according to claim 1 , wherein the hydrophobic acid is pamoic acid.

12. The therapeutic nanoparticle according to claim 1 comprising about 0.2 to about 30 weight percent of the PLA-PEG-GL.

13. The therapeutic nanoparticle according to claim 1 , wherein the substantially hydrophobic acid is a mixture of two or more substantially hydrophobic acids.

14. The therapeutic nanoparticle of claim 1 prepared by the process comprising the steps of:
emulsification of a first organic phase comprising a first polymer, a therapeutic agent, and a substantially hydrophobic acid, thereby forming an emulsion phase;
quenching of the emulsion phase thereby forming a quenched phase; and
filtration of the quenched phase to recover the therapeutic nanoparticles, wherein the therapeutic agent is 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea or a pharmaceutically acceptable salt thereof, wherein the substantially hydrophobic acid and the therapeutic agent form a hydrophobic ion pair in the therapeutic nanoparticle.

15. The therapeutic nanoparticle according to claim 1 , further comprising a solubilizer.

16. A pharmaceutical composition comprising a therapeutic nanoparticle according to claim 1 and a pharmaceutically acceptable excipient.

17. The pharmaceutical composition of claim 16 comprising a plurality of therapeutic nanoparticles.

Assignees

• Pfizer

Inventors

• Bagrodia Shubha
• LAFONTAINE Jennifer
• Lovatt Zach
• Shin Eyoung
• Song Young Ho
• Troiano Greg
• Wang Hong

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61P1/18

  for pancreatic disorders, e.g. pancreatic enzymes · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title